Novo Looks at Raising Obesity Sales Targets on Demand for Wegovy

Novo Nordisk A/S is considering raising the sales guidance for its obesity drugs after a strong introduction for its new medication called Wegovy, Chief Executive Officer Lars Fruergaard Jorgensen said in an interview.

“It’s fair to say that the prospects here are better than we have guided,” Jorgenson said. “The clinical profile was better than we anticipated, the market reception is very strong, and we also see that even in markets without Wegovy that the obesity market is also being established.”